Next Article in Journal
The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
Next Article in Special Issue
Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging Therapy
Previous Article in Journal
ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer
Previous Article in Special Issue
Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
cancers-logo
Article Menu

Article Menu

Article

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

1
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta
2
Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
3
Centre for Molecular Medicine & Biobanking, University of Malta, MSD 2080 Msida, Malta
4
Departments of Obstetrics and Gynaecology and Histopathology, Trinity St James’s Cancer Institute, Trinity College Dublin, Dublin 8, Ireland
5
Department of Obstetrics and Gynaecology, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta
6
Department of Pathology, Campo dos Mártires da Pátria, Instituto Portugues de Oncologia de Lisboa, NOVA Medical School, UNL, 130, 1169-056 Lisboa, Portugal
7
Genomic And Molecular Epidemiology (GAME) Lab., School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy
8
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, 9 Dublin, Ireland
9
Department of Gynecologic Oncology, Emsey Hospital, Istanbul 3400, Turkey
10
Directorate for Health Information and Research, PTA 1313 G’Mangia, Malta
11
Office of the Chief Medical Officer, Department of Policy in Health, Ministry for Health, 15 Merchants Street, VLT 1171 Valletta, Malta
12
Department of Obstetrics and Gynaecology, Mater Dei Hospital, Triq Dun Karm, MSD 2090 Msida, Malta
13
Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia
14
University of American College, 1000 Skopje, North Macedonia
15
Department of Gynecologic Oncology, Medical University Pleven, 5800 Pleven, Bulgaria
16
Department of Surgery, Alexandrovska University Hospital, 1431 Sofia, Bulgaria
17
Sir Anthony Mamo Oncology Centre, Department of Oncology and Radiotherapy, Mater Dei Hospital, MSD 2090 Msida, Malta
18
Department of Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuţă”. 34–36 Republicii Street, 400015 Cluj-Napoca, Romania
19
Department of Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
20
Department of Surgical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
21
Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj Napoca, Romania
22
Biomedical Research Foundation of the Academy of Athens, Soranou Efesiou 4 str., 11527 Athens, Greece
23
Institute of Obstetrics and Gynaecology, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary
24
Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
25
Centre of Molecular Medicine and BioBanking, Department of Physiology & Biochemistry, Faculty of Medicine & Surgery, University of Malta, MSD 2080 Msida, Malta
26
Beatson Oncology Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK
27
Cancer Research UK Edinburgh Centre, Western General Hospital, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK
28
Department of Statistics, University of Haifa, Haifa 31905, Israel
*
Author to whom correspondence should be addressed.
Academic Editors: Bo Ruben Rueda and Javier Martin-Broto
Cancers 2021, 13(3), 493; https://doi.org/10.3390/cancers13030493
Received: 31 December 2020 / Revised: 19 January 2021 / Accepted: 22 January 2021 / Published: 27 January 2021
(This article belongs to the Special Issue New Therapeutic Advances in Rare Tumors)
More than 50% of all the tumors affecting the female genital tract can be classified as rare and usually have a poor prognosis owing to delayed diagnosis and treatment. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different countries. The European Network for Gynecological Rare Cancer Research: GYNOCARE aims to address these challenges by creating a unique network between key stakeholders covering distinct domains from basic research to cure. GYNOCARE is part of a European Collaboration in Science and Technology (COST) with the aim to focus on the development of new approaches to improve the diagnosis and treatment of rare gynecological tumors. Here, we provide a brief overview describing the goals of this COST Action and its future challenges with the aim to continue fighting against this rare cancer.
More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on expert opinion, retrospective studies, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges through the creation of a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide. View Full-Text
Keywords: rare gynecologic tumors; circulating tumor-specific markers; cancer stem cells; theranostics; biobanking; personalized medicine rare gynecologic tumors; circulating tumor-specific markers; cancer stem cells; theranostics; biobanking; personalized medicine
Show Figures

Figure 1

MDPI and ACS Style

Di Fiore, R.; Suleiman, S.; Ellul, B.; O’Toole, S.A.; Savona-Ventura, C.; Felix, A.; Napolioni, V.; Conlon, N.T.; Kahramanoglu, I.; Azzopardi, M.J.; Dalmas, M.; Calleja, N.; Brincat, M.R.; Muscat-Baron, Y.; Sabol, M.; Dimitrievska, V.; Yordanov, A.; Vasileva-Slaveva, M.; von Brockdorff, K.; Micallef, R.A.; Kubelac, P.; Achimaș-Cadariu, P.; Vlad, C.; Tzortzatou, O.; Poka, R.; Giordano, A.; Felice, A.; Reed, N.; Herrington, C.S.; Faraggi, D.; Calleja-Agius, J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers 2021, 13, 493. https://doi.org/10.3390/cancers13030493

AMA Style

Di Fiore R, Suleiman S, Ellul B, O’Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimaș-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers. 2021; 13(3):493. https://doi.org/10.3390/cancers13030493

Chicago/Turabian Style

Di Fiore, Riccardo, Sherif Suleiman, Bridget Ellul, Sharon A. O’Toole, Charles Savona-Ventura, Ana Felix, Valerio Napolioni, Neil T. Conlon, Ilker Kahramanoglu, Miriam J. Azzopardi, Miriam Dalmas, Neville Calleja, Mark R. Brincat, Yves Muscat-Baron, Maja Sabol, Vera Dimitrievska, Angel Yordanov, Mariela Vasileva-Slaveva, Kristelle von Brockdorff, Rachel A. Micallef, Paul Kubelac, Patriciu Achimaș-Cadariu, Catalin Vlad, Olga Tzortzatou, Robert Poka, Antonio Giordano, Alex Felice, Nicholas Reed, C. S. Herrington, David Faraggi, and Jean Calleja-Agius. 2021. "GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions" Cancers 13, no. 3: 493. https://doi.org/10.3390/cancers13030493

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop